Cancer cells expressing mismatched HLA or tumor antigens

This target refers to a population of malignant cells characterized by the expression of either mismatched Human Leukocyte Antigen (HLA) molecules or specific tumor-associated antigens (TAAs). In the context of allogeneic hematopoietic stem cell transplantation, the mismatch between donor and recipient HLA serves as the primary driver for the Graft-versus-Tumor (GvT) effect, where donor-derived T cells recognize and eliminate residual cancer cells (Source: National Cancer Institute). Beyond HLA, these cells often express unique proteins such as NY-ESO-1, MAGE-A4, or CD19, which are utilized as specific targets for engineered immunotherapies like CAR-T and TCR-T cells (Source: Nature Reviews Cancer). The therapeutic interaction involves the binding of an immune receptor to these surface markers, triggering a cascade that results in the release of cytotoxic granules and subsequent apoptosis of the cancer cell (Source: PubMed). While highly effective for achieving remission, this strategy carries significant risks, most notably Graft-versus-Host Disease (GvHD) if the immune response extends to healthy host tissues (Source: NIH). Modern oncology focuses on refining the specificity of these interactions to maximize tumor clearance while minimizing systemic toxicity and overcoming mechanisms of immune evasion such as antigen loss.

Other names

HLA-mismatched malignant cellsAntigen-bearing tumor cellsAllogeneic cancer targetsTumor-antigen presenting cells

Recognition of non-self HLA or specific tumor-associated antigens by T-cell receptors (TCRs) or Chimeric Antigen Receptors (CARs), leading to perforin/granzyme-mediated cytotoxic cell death.